Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 198 for:    Venetoclax AND ABT-199

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01969682
Recruitment Status : Withdrawn (This study will be conducted in healthy volunteer subjects.)
First Posted : October 25, 2013
Last Update Posted : May 26, 2014
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
AbbVie

Brief Summary:
This is an open-label multicenter, study to assess the pharmacokinetic interaction of rifampin with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.

Condition or disease Intervention/treatment Phase
Non-Hodgkin's Lymphoma Drug: ABT-199 Drug: Rifampin Phase 1

Detailed Description:
This is a Phase 1 study designed to assess how the body processes the study drug ABT-199 when taken alone and in combination with rifampin and to assess the safety of ABT-199 in combination with rifampin. Subjects may enroll in a separate extension study to continue receiving ABT-199 after completion of this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199
Study Start Date : April 2014
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A (ABT-199 and rifampin) Drug: ABT-199
Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
Other Name: GDC-0199

Drug: Rifampin
Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin




Primary Outcome Measures :
  1. Determination of maximum observed plasma concentration (Cmax), time to Cmax (peak time, Tmax), terminal phase elimination rate constant (beta), terminal phase elimination half-life (t1/2), & area under the plasma concentration-time curve (AUC) of ABT-199 [ Time Frame: Measured pre-dose and up to 96 hours post-dose ABT-199 ]
    Blood samples for pharmacokinetic (PK) analysis of ABT-199 will be collected at designated timepoints to assess the PK parameters for ABT-199 alone relative to ABT-199 with rifampin


Secondary Outcome Measures :
  1. Number of subjects with adverse events [ Time Frame: Measured up to 30 days after the last dose of study drug ]
    Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study

  2. Percentage of subjects with adverse events [ Time Frame: Measured up to 30 days after the last dose of study drug ]
    Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study

  3. Change in physical exam finding, including vital signs [ Time Frame: Measured from Day 1 up to 30 days after the last dose of study drug ]
    Body temperature, weight, blood pressure, heart rate

  4. Change in clinical laboratory test results [ Time Frame: Measured from Day 1 up to 30 days after the last dose of study drug ]
    Chemistry, coagulation, hematology, urinalysis

  5. Change in cardiac assessment findings [ Time Frame: Measured from Day 1 up to Day 19 ]
    Electrocardiogram



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must have relapsed or refractory non-Hodgkin's lymphoma.
  • Subject must have histologically documented diagnosis of non-Hodgkin's lymphoma as defined by a B-cell neoplasm in the World Health Organization (WHO) classification scheme except as noted in the exclusion criteria.
  • Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2.
  • Subject must have adequate bone marrow (independent of growth factor support per local laboratory reference range), coagulation, renal and hepatic function:

    • Absolute Neutrophil Count (ANC) greater than or equal to 1000/µL (without growth factor support unless neutropenia is clearly due to underlying disease);
    • Platelets greater than or equal to 75,000/mm3 (unless thrombocytopenia is clearly due to disease-related immune thrombocytopenia or to underlying disease; entry platelet count must be independent of transfusion within 14 days of Screening);
    • Hemoglobin greater than or equal to 9.0 g/dL (unless anemia is clearly due to underlying disease; entry hemoglobin must be independent of transfusion within 14 days of Screening);
    • If cytopenias are present, no evidence of myelodysplastic syndrome or hypoplastic bone marrow;
    • Subject must have activated partial thromboplastin time (aPTT) and prothrombin time (PT) not to exceed 1.5 × the upper normal limit (ULN);
    • Calculated creatinine clearance greater than or equal to 50 mL/min using a 24-hour urine collection for creatinine clearance or per the Cockcroft-Gault equation;
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 3.0 × ULN of institution's normal range;
    • Bilirubin less than or equal to 1.5 × ULN. Subjects with Gilbert's Syndrome may have a bilirubin greater than 1.5 × ULN per discussion with the AbbVie medical monitor.

Exclusion Criteria:

  • Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease (PTLD), Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL).
  • Subject is receiving combination anti-retroviral therapy for HIV (due to potential drug-drug interactions between anti-retroviral medications and ABT-199, as well as anticipated ABT-199 mechanism based lymphopenia that may potentially increase the risk of opportunistic infections).
  • Subject has hypersensitivity to any of the rifamycins.
  • Subject has a cardiovascular disability status of New York Heart Association Class greater than or equal to 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea or anginal pain.
  • Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease within the past 6 months that in the opinion of the investigator would adversely affect his/her participating in this study.
  • Subject has malabsorption syndrome or other condition which precludes enteral route of administration (e.g., prior surgical resection).
  • Subject has undergone an allogeneic stem cell transplant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01969682


Locations
Layout table for location information
United States, New Jersey
Site Reference ID/Investigator# 101416
Hackensack, New Jersey, United States, 07601
Sponsors and Collaborators
AbbVie
Genentech, Inc.
Investigators
Layout table for investigator information
Study Director: David Chien, MD AbbVie

Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT01969682     History of Changes
Other Study ID Numbers: M13-366
First Posted: October 25, 2013    Key Record Dates
Last Update Posted: May 26, 2014
Last Verified: May 2014
Keywords provided by AbbVie:
non-Hodgkin's lymphoma
GDC-0199
Safety
Relapsed
Refractory
ABT-199
Pharmacokinetics
Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Venetoclax
Lymphoma, Non-Hodgkin
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rifampin
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers
Antineoplastic Agents